Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Tumour-infiltrating lymphocytes (TILs) are considered crucial in anti-tumour immunity.
Accordingly, the presence of TILs contains prognostic and predictive value. In 2011, we …

T follicular helper (Tfh) cells provide essential help to B cells for effective antibody-mediated
immune responses. Although the crucial function of these CD4+ T cells in infection and …

The advent of chimeric antigen receptor (CAR) T cell therapy has resulted in unprecedented
long-term clearance of relapse/refractory hematological malignancies in both pediatric and …

Immunosuppressive regulatory T cells (Tregs) provide a main mechanism of tumor immune
evasion. Targeting Tregs, especially in the tumor microenvironment (TME), continues to be …

Although advances in spatial transcriptomics (ST) enlarge to unveil spatial landscape of
tissues, it remains challenging to delineate pathology-relevant and cellular localizations …

Our understanding of tumor-infiltrating lymphocytes (TILs) is rapidly expanding beyond T cell-
centric perspectives to include B cells and plasma cells, collectively referred to as TIL-Bs. In …

The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and
programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to …

Regulatory T (Treg) cells, possess a strategic role in the maintenance of immune
homeostasis, and their function has been closely linked to development of diverse …